Australia Pharmaceutical Market by Product Type, Distribution Channel, End User 2024-2032
                     Australia Pharmaceutical 
Market Research and 
Forecast Report 2024-
2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
IMARC Group is  a g lobal  management  consul t ing f i rm that  he lps the wor ld ’s  most  ambi t ious 
changemakers  to create a las t ing impact .  Across the s ix  major  cont inents  and 100+ count r ies ,  we 
work a longside our  bus iness par tners  as one team wi th  a common ambi t ion to achieve unparal le led 
resul ts ,  gain a compet i t ive edge,  and t ransform indust r ies .  IMARC Group excels  in  unders tanding 
i ts  c l ients ’  bus iness pr ior i t ies  and del iver ing ta i lored solut ions that  dr ive meaningfu l  outcomes.  Our 
c l ient  base spans over  3,000 organizat ions in  the pr ivate,  publ ic ,  and soc ia l  sectors ,  ranging f rom 
high-growth s tar tups to For tune 500 companies.
We prov ide a comprehensive sui te of  market  entry  and expansion serv ices.  Our of fer ings inc lude 
thorough market  assessment ,  feas ib i l i ty  s tudies,  company incorporat ion ass is tance,  fac tory  setup 
suppor t ,  regulatory  approvals and l icens ing navigat ion,  branding,  market ing and sales st rategies,  
compet i t ive landscape and benchmark ing analyses,  pr ic ing and cost  research,  and procurement  
research.  These serv ices are des igned to ass is t  companies in  evaluat ing market  oppor tuni t ies ,  
set t ing up new ent i t ies ,  navigat ing regulatory landscapes,  boost ing brand v is ib i l i ty ,  analyz ing 
compet i tors,  and opt imiz ing procurement  s t rategies.
Acco r d ing  t o  t h e  l a t es t  r epo r t  by  I M ARC G r o up ,  t i t l ed  "A ust r a l i a  Phar mac eut i ca l  
M ar ke t :  I nd ust ry  T r ends ,  Sha re ,  S i ze ,  G row t h ,  O ppo r t un i t y  a nd  For ecas t  202 4 -
2032 , "  t he  Aus t r a l i a  pha r m ac eu t i c a l  m ar k e t  s i ze  i s  p r o jec t ed  t o  exh ib i t  a  g r ow t h  r a t e  
( CAG R)  o f  2 . 6 0% du r in g  20 24 - 20 32 .
Report Aus t r a l i a  pha r m ac eu t i ca l  m ar ke t  i s  ex pe r ien c ing  s ign i f i can t  g r ow t h  f ue led  b y  sev e r a l  
key  f ac t o r s .  F i r s t l y ,  a  con f l uence  o f  dem ogr ap h ics  an d  g ov e r nm en t  po l i c y  i s  d r i v i ng  
dem and  f o r  m e d ica t i ons .  T he  co un t r y  ag ing  popu la t i on  f aces  a  r i s i ng  p r eva le nce  o f  
Highlight and ch r o n i c  d i sease s  l i ke  hea r t  d i s ease  and  d iabe t es .  
Th i s  n eces s i t a t e s  ongo ing  a ccess  t o  a  b r oad  r ange  o f  m ed i ca t i on s ,  bo t h  i n nova t i ve  
Description and  gene r i c .  F o r t un a t e l y ,  Au s t r a l i a ' s  gove r nm e n t  hea v i l y  su bs id i ze s  p r e sc r i p t i on  d r ug s  t h r ough  t he  P ha r m aceu t i ca l  Ben e f i t s  Sche m e ( PBS ) ,  m a k ing  t h em  m or e  
a f f o r dab le  f o r  c i t i zens .  Th i s  no t  on l y  im p r oves  p ub l i c  h ea l t h  o u t co m es  bu t  a l so  
c r ea t es  a  gua r an t e ed  m ar k e t  f o r  ph a r m a ceu t ic a l  co m pa n ies .
Reque st  f o r  a  PDF  sam pl e  o f  t h i s  re por t :  
h t t p s : / / www. im ar c g r ou p . com / aus t r a l i a - pha r m ac eu t i ca l - m a r ke t / r equ es t sa m p le
Report Description
Austral ia  Pharmaceut ical  Market  Trends:
Secondly ,  Aust ra l ia  robust  regula tory  f ramework fos ters  t rus t  and innovat ion wi th in  the market .  The 
Therapeut ic  Goods Admin is t ra t ion (TGA) enforces s t r ic t  safe ty  and qual i ty  s tandards for  a l l  
pharmaceut ica ls .  Th is  ensures consumers have access to  safe and ef fect ive medicat ions,  fos ter ing t rus t  in  
the indust ry .  
Fur thermore,  Aust ra l ia 's  s t rong emphas is  on research and development  (R&D) fue ls  innovat ion.  S ign i f icant  
investments  are d i rec ted towards b io technology and pharmaceut ica l  research,  lead ing to  the development  
o f  new and advanced t reatments.  Th is  focus on innovat ion not  on ly  expands the market  w i th  novel  drugs 
but  a lso pos i t ions Aust ra l ia  as  a  potent ia l  expor ter  in  the g lobal  pharmaceut ica l  landscape.
View Report  TOC,  F igures and Tables :  ht tps: / /www.imarcgroup.com/austral ia-pharmaceut ical -market
Therapeutic Class Insights:
• Alimentary Tract  and Metabol ism
• Blood and Blood Forming Organs
• Cardiovascular System
• Dermatologicals
• Genito Urinary System and Sex Hormones
Report • Systemic Hormonal Preparations
• Anti- infect ives for Systemic Use
Segmentation • Antineoplast ic and Immunomodulating Agents
• Musculoskeletal  System
• Nervous System
• Antiparasit ic Products,  Insect ic ides,  and 
Repel lents
• Respiratory System
• Sensory Organs
• Others
Drug Type Insights:
• Branded
• Generic
Prescription Type Insights:
• Prescript ion Drugs (Rx)
Report • OTC Drugs
Segmentation
Regional Insights:
• Austral ia Capital  Terr i tory & New South Wales
• Victoria & Tasmania
• Queensland
• Northern Terr i tory & Southern Austral ia
• Western Austral ia
How has the Australia pharmaceutical market 
performed so far and how will it perform in the coming 
years?
What has been the impact of COVID-19 on the Australia 
pharmaceutical market?
What is the breakup of the Australia pharmaceutical 
market on the basis of therapeutic class?
Key 
What is the breakup of the Australia pharmaceutical 
market on the basis of drug type?
Questions 
What is the breakup of the Australia pharmaceutical 
Answered in market on the basis of prescription type?
the Report What are the various stages in the value chain of the 
Australia pharmaceutical market? 
What are the key driving factors and challenges in the 
Australia pharmaceutical?
What is the structure of the Australia pharmaceutical 
market and who are the key players?
What is the degree of competition in the Australia 
pharmaceutical market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
Table of         2 . 4 . 1     B o t t o m - U p  A p p r o a c h        2 . 4 . 2     T o p - D o w n  A p p r o a c h
    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4    A u s t r a l i a  P h a r m a c e u t i c a l  M a r k e t  -  I n t r o d u c t i o n
Contents     4 . 1     O v e r v i e w    4 . 2     M a r k e t  D y n a m i c s
    4 . 3     I n d u s t r y  T r e n d s
    4 . 4     C o m p e t i t i v e  I n t e l l i g e n c e
5    A u s t r a l i a  P h a r m a c e u t i c a l  M a r k e t  L a n d s c a p e
    5 . 1     H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
    5 . 2     M a r k e t  F o r e c a s t  (  2 0 2 4 - 2 0 3 2 )
6    A u s t r a l i a  P h a r m a c e u t i c a l  M a r k e t  -  B r e a k u p  b y  T h e r a p e u t i c  C l a s s
    6 . 1     A l i m e n t a r y  T r a c t  a n d  M e t a b o l i s m
        6 . 1 . 1  O v e r v i e w
        6 . 1 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 1 . 3  M a r k e t  F o r e c a s t  (  2 0 2 4 - 2 0 3 2 )
    6 . 2     B l o o d  a n d  B l o o d  F o r m i n g  O r g a n s
        6 . 2 . 1  O v e r v i e w
        6 . 2 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 2 . 3  M a r k e t  F o r e c a s t  (  2 0 2 4 - 2 0 3 2 )
       
    6 . 3     C a r d i o v a s c u l a r  S y s t e m
        6 . 3 . 1  O v e r v i e w
        6 . 3 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 3 . 3  M a r k e t  F o r e c a s t  (  2 0 2 4 - 2 0 3 2 )
    6 . 4     D e r m a t o l o g i c a l s
        6 . 4 . 1  O v e r v i e w
        6 . 4 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 4 . 3  M a r k e t  F o r e c a s t  (  2 0 2 4 - 2 0 3 2 )
    6 . 5     G e n i t o  U r i n a r y  S y s t e m  a n d  S e x  H o r m o n e s
        6 . 5 . 1  O v e r v i e w
        6 . 5 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 5 . 3  M a r k e t  F o r e c a s t  (  2 0 2 4 - 2 0 3 2 )
Table of     6 . 6     S y s t e m i c  H o r m o n a l  P r e p a r a t i o n s
        6 . 6 . 1  O v e r v i e w
        6 . 6 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
Contents         6 . 6 . 3  M a r k e t  F o r e c a s t  (  2 0 2 4 - 2 0 3 2 )    6 . 7     A n t i - i n f e c t i v e s  f o r  S y s t e m i c  U s e
        6 . 7 . 1  O v e r v i e w
        6 . 7 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 7 . 3  M a r k e t  F o r e c a s t  (  2 0 2 4 - 2 0 3 2 )
    6 . 8     A n t i n e o p l a s t i c  a n d  I m m u n o m o d u l a t i n g  A g e n t s
        6 . 8 . 1  O v e r v i e w
        6 . 8 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 8 . 3  M a r k e t  F o r e c a s t  (  2 0 2 4 - 2 0 3 2 )
    6 . 9     M u s c u l o s k e l e t a l  S y s t e m
        6 . 9 . 1  O v e r v i e w
        6 . 9 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 9 . 3  M a r k e t  F o r e c a s t  (  2 0 2 4 - 2 0 3 2 )
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
ht t ps : / /www. i m a rc gro up . c o m/a us t ra l i a -pha rma ce ut i c a l -m a rke
t / t o c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: